Last reviewed · How we verify

NCT03899532: MOTION

Remote Ischemic Conditioning in Traumatic Brain Injury

Withdrawn NA Last updated 4 April 2025
What this trial tests

NA trial testing Remote Ischemic Conditioning in Traumatic Brain Injury. Withdrawn.

Timeline
24 September 2019
Primary endpoint
30 May 2023
30 May 2023

Quick facts

Lead sponsorUniversity of Arizona
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Start date24 September 2019
Primary completion30 May 2023
Estimated completion30 May 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Arizona

Who can join

17 and older, any sex, with Traumatic Brain Injury or Brain Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Traumatic brain injury (TBI) is a leading cause of death among trauma patients accounting for one-third of all trauma mortalities. Patients who survive the initial trauma are liable to secondary insults from the ensuing inflammatory state in the brain. Treatment goals are aimed at reducing secondary injury. Maintaining adequate brain perfusion, limiting cerebral edema, and optimizing oxygen delivery are part of established treatment protocols. Numerous therapeutics have been evaluated as potential treatment for TBI with very limited success and there is no medication that alters survival. Various novel therapeutic options have been investigated to prevent the secondary brain injury. Remote Ischemic Conditioning (RIC) is one of these therapies. RIC involves decreasing blood flow to a normal tissue usually the arm by inflating the blood pressure cuff 30mmHg over the systolic blood pressure. The decreased blood flow or ischemia is maintained for 5 minutes followed by releasing the pressure and re-perfusion of the arm. This cycle is usually repeated 4 times. RIC has been shown to improve outcomes in patients with heart attacks, strokes, elective neurosurgeries. A prospective observational study and a randomized clinical trial has shown the protective effect of RIC in TBI patients. Additionally, multiple studies in animals have shown that RIC is neuroprotective after TBI. RIC is non-invasive and harmless except for a little discomfort in the arm. The aim of the study is to evaluate the impact of RIC on long term outcomes in patients with TBI.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Advances in development of biomarkers for brain damage and ischemia.
    Karimova D, Rostami E, Chubarev VN, Tarasov VV, et al · · 2024 · cited 5× · PMID 39001884 · DOI 10.1007/s11033-024-09708-x

Verify or expand the search:

Other trials of Remote Ischemic Conditioning

Trials testing the same drug.

Other recruiting trials for Traumatic Brain Injury

Currently open trials in the same condition.

Other University of Arizona trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing